

INVITATION ORDINARY GENERAL MEETING CAVOTEC SA



OGM location

Cavotec SA - Via Balestra 27, Lugano

Information meeting location

Wallenbergsalen – IVA Conferenscenter
Grev Turegatan 16, Stockholm

Friday, April 22, 2016

LOCATION AND TIME

Information meeting

Friday, April 22, 2016


10:30 CET (doors open at 10.15 CET).

In the morning of April 22, 2016, an information meeting will be hosted at the IVA Conferenscenter, Grev Turegatan 16 in Stockholm, Sweden. This meeting is open to shareholders and interested parties and will feature an update on Cavotec's recent business activities.

At 12:00 CET a passive video-stream of the OGM will be projected for shareholders who are unable to attend the OGM held in Lugano.

Wallenbergsalen – IVA Conferenscenter

Grev Turegatan 16 – 102 42 Stockholm



Ordinary General Meeting

Friday, April 22, 2016

12:00 CET (doors open at 11.30 CET).


The OGM will take place at Cavotec SA headquarters in Lugano, Switzerland.

Shareholders are invited to review the various ways how to participate to the OGM and cast their vote. Information on this can be found on page 6 to 9 of this invitation.

Please note that during the OGM no interaction (i.e. voting, questions etc.) will be possible from outside of the meeting held in Lugano, namely from persons following the video-stream in Stockholm.

Cavotec SA – Headquarters

Via Balestra 27 – 6900 Lugano



For questions regarding participation to the OGM, please contact:

Cavotec SA – c/o Euroclear Sweden AB – Box 191 – SE-10123 Stockholm, Sweden – Telephone: +46 84029283

TO THE SHAREHOLDERS OF CAVOTEC SA: INVITATION TO THE ORDINARY GENERAL MEETING

AGENDA AND PROPOSALS OF THE BOARD OF DIRECTORS

It is proposed the Ordinary General Meeting (OGM) to be chaired by Fabio Cannavale .

1. Annual report, financial statements and consolidated financial statements for the year 2015, report of the Statutory Auditors

The Board of Directors proposes that the annual report, the financial statements and the consolidated financial statement for the year 2015 be approved.

2. Appropriation of available earnings

The Board of Directors proposes the following appropriation:

CHF

Carried forward from previous years	(7,645,835)
Net gain/loss for the financial year 2015	(11,067,235)
Total earnings available	(18,713,070)
<hr/>	
Appropriation to general statutory reserves (retained earnings)	-
Appropriation to other reserves	-
Proposed balance to be carried forward	(18,713,070)

3. Grant of Discharge from Liability to the Board of Directors and Persons entrusted with the Management from Activities during Business Year 2015

The Board of Directors proposes that discharge be granted to all the members of the Board of Directors and the Persons entrusted with the Management for the business year 2015.

4. Capital reduction through partial nominal value repayment

The Board of Directors proposes:

- to reduce the current share capital of CHF 108,379,680.00 by CHF 2,356,080 to CHF 106,023,600 by way of reducing the nominal value of the registered shares from CHF 1.38 by CHF 0.03 to CHF 1.35 and to use the nominal value reduction amount for repayment to the shareholders;
- to confirm as a result of the report of the auditors, that the claims of the creditors are fully covered notwithstanding the capital reduction;
- to amend article 4, article 4ter, article 4quater para. 1, article 4quinquies, article 4sexies and article 4septies of the Articles of Association according to the following wording as per the date of the entry of the capital reduction in the commercial register (the proposed amendments are in italics):

Article 4

“The share capital of the Company is CHF 106,023,600 and is divided into 78,536,000 fully paid registered shares. Each share has a par value of CHF 1.35.”

Article 4ter

“The share capital may be increased in an amount not to exceed CHF 963,862.20 through the issuance of up to 713,972 fully paid registered shares with a par value of CHF 1.35 per share by the issuance of new shares to employees of the Company and group companies. The pre-emptive rights and advance subscriptions rights of the shareholders of the Company shall thereby be excluded. The shares or rights to subscribe for shares shall be issued to employees pursuant to the Long Term Incentive Plan approved by the Board of Directors. Shares or subscription rights may be issued to employees at 10% discount compared with the market price quoted on the stock exchange of that time.”

Article 4quater para. 1

“The Board of Directors shall be authorized to increase the share capital in an amount not to exceed CHF 9,639,896.40 through the issuance of up to 7,140,664 fully paid registered shares with a par value of CHF 1.35 per share by not later than April 23, 2016.”

Article 4quinquies

“The share capital may be increased in an amount not to exceed CHF 963,862.20 through the issuance of up to 713,972 fully paid registered shares with a par value of CHF 1.35 per share by the issuance of new shares to employees of the Company and group companies. The pre-emptive rights and advance subscriptions rights of the shareholders of the Company shall thereby be excluded. The shares or rights to subscribe for shares shall be issued to employees pursuant to the Long Term Incentive Plan 2013 approved by the Board of Directors. Shares or subscription rights may be issued to employees at 10% discount compared with the market price quoted on the stock exchange of that time.”

Article 4sexies

“The share capital may be increased in an amount not to exceed CHF 963,862.20 through the issuance of up to 713,972 fully paid registered shares with a par value of CHF 1.35 per share by the issuance of new shares to employees of the Company and group companies. The pre-emptive rights and advance subscriptions rights of the shareholders of the Company shall thereby be excluded. The shares or rights to subscribe for shares shall be issued to employees pursuant to the Long Term Incentive Plan 2014 approved by the Board of Directors. Shares or subscription rights may be issued to employees at 10% discount compared with the market price quoted on the stock exchange of that time.”

Article 4septies

“The share capital may be increased in an amount not to exceed CHF 1,060,236.00 through the issuance of up to 785,360 fully paid registered shares with a par value of CHF 1.35 per share by the issuance of new shares to employees of the Company and group companies. The pre-emptive rights and advance subscriptions rights of the shareholders of the Company shall thereby be excluded. The shares or rights to subscribe for shares shall be issued to employees pursuant to the Long Term Incentive Plan 2015 approved by the Board of Directors. Shares or subscription rights may be issued to employees at 10% discount compared with the market price quoted on the stock exchange of that time.”

Explanatory notes:

In the event of approval of the proposed capital reduction, the nominal value reduction amount shall be repaid to shareholders. The capital reduction will be implemented after publication of the general meeting resolution in the Swiss Official Gazette of Commerce in accordance with Art. 733 Swiss Code of Obligations and the expiration of the 2 months notice period provided therein. Subject to approval by the general shareholders' meeting and to entry of the reduction in the Commercial Register, CHF 0.03 per share will be repaid to the shareholders, holding shares on July 4 prospectively on July 11, 2016. The capital reduction amount is paid out without deduction of Swiss withholding tax.

5. Creation of additional contingent share capital in connection with employee participation

The Board of Directors proposes to create additional contingent share capital in an amount not to exceed CHF 1,060,236.00 enabling the issuance of up to 785,360 additional shares with a nominal value of CHF 1.35 each in connection with employee participation by inserting the new article 4octies of the Articles of Association to read as follows:

“Article 4octies – Contingent Share Capital

The share capital may be increased in an amount not to exceed CHF 1,060,236.00 through the issuance of up to 785,360 fully paid registered shares with a par value of CHF 1.35 per share by the issuance of new shares to employees of the Company and group companies. The pre-emptive rights and advance subscriptions rights of the shareholders of the Company shall thereby be excluded. The shares or rights to subscribe for shares shall be issued to employees pursuant to the Long Term Incentive Plan 2016 approved by the Board of Directors. Shares or subscription rights may be issued to employees at a 10% discount compared with the market price quoted on the stock exchange of that time.”

Explanatory notes:

The proposed additional new contingent share capital is intended to help Cavotec SA retaining key managers in connection with Cavotec SA's Long Term Incentive Plan 2016 (LTIP 2016). The Chairman of the Remuneration Committee will present the LTIP 2016 in detail at the OGM. Information regarding the LTIP is available on www.cavotec.com.

6. Creation of authorized share capital

The Board of Directors proposes to create authorized share capital in an amount not to exceed CHF 21,204,720, enabling the issuance of up to 15,707,200 Cavotec SA shares by not later than April 22, 2018, by amending article 4quater, para. 1 of the Articles of Association with the following wording:

“The Board of Directors shall be authorized to increase the share capital in an amount not to exceed CHF 21,204,720 through the issuance of up to 15,707,200 fully paid registered shares with a par value of CHF 1.35 per share by not later than April 22, 2018. Increases in partial amounts shall be permitted.”

Explanatory notes:

The current provision regarding authorized share capital, article 4ter of the Articles of Association, has been approved by the AGM 2012 and renewed by the OGM 2014 and allowed for the creation of authorized capital for up to 14,279,444 shares, corresponding to 20% of all issued shares. Since then, the authorized share capital has been used for the issuing of 7,138,780 new shares that were subscribed by Bure Equity AB, as per Cavotec's press release of September 12, 2014. The authorized share capital is intended to enhance Cavotec SA's financial flexibility, in view of future acquisitions, while also enhancing the liquidity of the Cavotec share. Since the deadline of the authorized share capital approved in 2012 and renewed in 2014 will expire shortly, the purpose of this amendment is, on one hand, to extend said deadline for another two years. Furthermore, the Board of Directors proposes to rebuild and adapt the maximum number of shares to be issued under this article taking into account the currently issued shares. The proposed 15,707,200 correspond to 20% of all currently issued shares of Cavotec SA.

7. Approval of Remuneration

According to Art. 16b of the Articles of Association, the general meeting of shareholders shall annually approve the maximum aggregate amount (covering fixed and variable remuneration) each of:

- the remuneration for the Board of Directors for the next business year;
- the remuneration for the CEO for the next business year.

7.1 Approval of Remuneration for the Board of Directors

The Board of Directors proposes to approve the aggregate amount of CHF 1,000,000 for the remuneration for the Board of Directors for the business year 2017. Please note that this amount does not include the remuneration of the CEO (who is also member of the Board of Directors). The total aggregate amount of the CEO's remuneration is set forth in section 7.2.

7.2 Approval of Remuneration of the CEO

The Board of Directors proposes to approve the aggregate amount of CHF 1,200,000 for the remuneration for the CEO for the business year 2017.

8. Re-election of seven Directors, election of two new Directors and nomination of the Chairman of the Board of Directors

Pursuant to Art. 13 of the Articles of Association the directors are elected each year to hold office until the following annual shareholders' meeting. Directors may be re-elected.

Fabio Cannavale, Leena Essén, Nicola Gerber, Erik Lautmann, Ottonel Popesco, Patrik Tigerschiöld and Stefan Widegren stand for re-election. Christer Granskog and Lakshmi C. Khanna do not stand for re-election.

The Board of Directors, based on the recommendation of the Nomination Committee, proposes that Fabio Cannavale, Leena Essén, Nicola Gerber, Erik Lautmann, Ottonel Popesco, Patrik Tigerschiöld and Stefan Widegren be re-elected as Directors for a further one-year term of office expiring at the OGM to be held in 2017.

In addition, the Board of Directors proposes, based on the recommendation of the Nomination Committee, that Héléna Thrap-Olsen and Heléne Mellquist be elected as Directors for a one-year of office expiring at the OGM to be held in 2017. A summary of curriculum vitae of Ms. Héléna Thrap-Olsen and of Heléne Mellquist can be found here below.

The Board of Directors, based on the recommendation of the Nomination Committee, furthermore proposes to nominate Stefan Widegren as Chairman of the Board of Directors.

With respect to the requirements in the Swedish Corporate Governance Code (the Code) that a majority of the directors elected by the shareholders' meeting are to be independent of the company and its executive management and that at least two of this majority also are to be independent in relation to the company's major shareholders, the Nomination Committee has carried out the following assessment:

Fabio Cannavale, Nicola Gerber, Héléna Thrap-Olsen, Heléne Mellquist, Erik Lautmann and Patrik Tigerschiöld are all independent of the company and its executive management.

Nicola Gerber, Héléna Thrap-Olsen and Heléne Mellquist and Erik Lautmann are all also independent in relation to the company's major shareholders.

The Nomination Committee therefore concludes that all requirements of director independence as set out in the Code are met. Shareholders representing more than 40% of the votes support the above-mentioned proposals made by the Nomination Committee.

Summary of Curriculum Vitae:

Heléne Mellquist

Heléne holds a BA in International Business Administration at the University of Gothenburg and completed the Executive Program IFL at Handelshögskolan in Stockholm. She is currently the MD of BizDrive AB. Prior to this role Heléne was CEO of TransAtlantic AB, CFO of Rederi AB TransAtlantic and also CFO at Volvo Lastvagnars International division. She has also held a number of leading positions within Volvo Group. Heléne is also a Board Member of Opus Group AB, TransAtlantic AB and Svensk Sjöfart.

Helena Thrap-Olsen

Helena holds a M.A. in Philosophy from Paris University and an International Marketing degree from INSEAD. She currently works since 2009 for Veolia's head office in Paris, in charge of the organization's global pooling and outsourcing programs: HRIS, Payroll and ATS International deployments, along with various corporate cross-functional HR projects. Prior to her role with Veolia, Helena was 10 years a Country Director for a BONNIER owned publishing company in France, followed by ten years as a Project Director/HR Change Management Consultant for various consulting companies.

9. Nominations for the Remuneration Committee

Pursuant to Art. 13 of the Articles of Association the members of the Remuneration Committee are elected each year to hold office until the following annual shareholders' meeting. Members of the Remuneration Committee may be re-elected.

The Board of Directors, based on the recommendation of the Nomination Committee, proposes that Erik Lautmann, Hélène Thrap-Olsen and Patrik Tigerschiöld be elected as members of the Remuneration Committee. As Chairman of Cavotec SA, Stefan Widegren will be invited to Remuneration Committee meetings.

With respect to the requirements in the Code that all members of the Remuneration Committee, apart from the chairman of the Remuneration Committee, are to be independent of the company and its executive management, the Nomination Committee has come to the conclusion that all candidates proposed by the Board of Directors are independent of the company and its executive management.

10. Re-election of Independent Auditor

The Board of Directors, based on the recommendation of the Nomination Committee, proposes that PricewaterhouseCoopers SA, Lugano, Switzerland be re-elected as Cavotec's independent auditor for business year 2016.

11. Election of an Independent Proxy

Pursuant to Art. 9a of the Articles of Association the Independent Proxy is elected each year to hold office until the following annual shareholders' meeting. The Independent Proxy may be re-elected.

The Board of Directors proposes that Mr. Franco Brusa, Attorney-at-law, Via G.B. Pioda 5, Lugano, Switzerland be re-elected as Cavotec's independent proxy for an additional one-year term expiring at the OGM 2017.

DOCUMENTATION AND ATTENDANCE PROCEDURES

Documentation

The 2015 Annual Report (including our audited consolidated financial statements for the business year ended December 31, 2015 and the auditor's report thereon), the audited statutory accounts of Cavotec SA for the business year ended December 31, 2015 and the auditor's report thereon as well as the remuneration report and the auditor's report thereon will be available for inspection by shareholders at our registered office at Via Balestra 27, 6900 Lugano, Switzerland beginning no later than February 26, 2016 and will be available at the OGM. Shareholders may also request copies of these documents at no cost, by writing or telephoning our offices at Cavotec SA, Via Balestra 27, 6900 Lugano Attn: Company Secretary, Telephone: +41 91 911 4010, Facsimile: +41 91 922 5400.

Materials for the 2016 OGM of Shareholders are also available on the Company's website ir.cavotec.com.

Language

The OGM, deviating from the Code, will be held in English and information and material will be available in English only. This is in accordance with an exemption granted by the Swedish Financial Supervisory Authority.

Participation

The OGM will take place in Lugano, Switzerland. For shareholders not wishing to personally attend to the OGM, an information meeting will be held in the morning of April 22, 2016, in Stockholm. After the information meeting, a (passive) video-stream of the OGM will be projected. However, shareholders attending the information meeting will not be attending to the OGM and should therefore exercise their voting rights through a proxy instructed either in writing or electronically. Please see below for detailed instructions for participation.

Please note that, during the OGM, every shareholder has the right to request information from the Board of Directors that is necessary for the exercise of the shareholders' rights. In accordance with Section 6 of the Swiss Code of Best Practice for Corporate Governance, shareholders intending to ask complex or an extensive range of questions are strongly requested to submit such questions in writing and well in advance of the meeting, in order for the Board of Directors to be able to review the admissibility and, if the case may be, give precise answers to such questions. The Board of Directors reserves the right to restrict the shareholders' right to ask questions and to answer in writing after the meeting instead in case an immediate answer is not possible or if the time allocated to questions has expired.

Electronic Proxy

On the website <http://anmalan.vpc.se/Cavotec2016> shareholders have the possibility to appoint the independent proxy and to give him instructions electronically. Registered shareholders will receive their personal login data ("the "Individual Login") by regular mail. The proxy granted electronically (the "Electronic Proxy") has the same validity as the physical Proxy Form. Please note that you cannot vote twice (electronically and by mail); the instructions (electronic or by mail) which have been given later prevail. Additional information on the Electronic Proxy is available on <http://anmalan.vpc.se/Cavotec2016>.

Instructions to participate for Holders of SIX SIS registered shares

The following information is to shareholders who hold their Cavotec shares through SIX SIS AG.

To attend the OGM and exercise your voting right, you must be registered in the share register of Cavotec SA ("Share Register") and complete the Proxy Form in accordance with the instructions set out below.

1. Registration in the Share Register of Cavotec SA:

In order to be entitled to voting rights at the OGM, Shareholders who are not already registered in the Share Register must request to be registered as shareholders in the Share Register prior to April 13, 2016 (the "Record Date") in accordance with the instructions set out below:

- Shareholders must instruct their custodian bank to register them as shareholders in the Share Register of Cavotec SA by sending a Proxy Form to Cavotec SA, c/o SIX SAG AG, Share Register, Baslerstrasse 90, CH-4601 Olten.
- The registration in the Share Register may be requested at any time.
- The registration must be completed on the Record Date at the latest.

Shareholders who are already registered in the Share Register do not have to perform any additional steps and will be provided automatically with the Proxy Form as well as with the Individual Login.

Please note that the registration process may take time. To ensure their registration in time for the OGM, shareholders are therefore kindly invited to issue instructions to their custodian bank as soon as possible.

2. Registration/Proxy Voting:

Shareholders, who are registered in the Share Register, will receive a Proxy Form as well as the Individual Login by regular mail directly from Cavotec SA. Shareholders will be able to appoint the independent proxy, Mr. Franco Brusa, Attorney-at-law, Via G.B. Pioda 5, Lugano, Switzerland or a third person as proxy or register to attend the OGM by using physical Proxy Forms. Alternatively, shareholders will also be able to appoint the independent proxy electronically on <http://anmalan.vpc.se/Cavotec2016>.

- The Proxy Form will be sent out via regular mail on March 7, 2016.
- In order to attend the OGM or vote by proxy, the Proxy Form must be returned to Cavotec SA, c/o Euroclear Sweden AB, PO Box 191, SE-101 23 Stockholm, Sweden or (in case of a proxy conferred to the independent proxy) to Mr. Franco Brusa c/o Euroclear Sweden AB, PO Box 191, SE-101 23 Stockholm, Sweden, well in advance of April 13, 2016. In order to vote by Electronic Proxy, the Electronic Proxy must be completed according to the instructions set out on <http://anmalan.vpc.se/Cavotec2016> by April 21 at the latest.

3. Access to the OGM and Voting Rights

To be granted access to the OGM, the Proxy Form must be filled out and returned in accordance with the instructions set out above.

Instructions to participate for Holders of Euroclear Sweden registered shares

The following information is to shareholders who hold their Cavotec shares through Euroclear Sweden AB, which shares trade on the NASDAQ OMX Stockholm Exchange ("Euroclear Registered Cavotec Shares").

To attend the OGM and exercise your voting right, you must register your voting rights in the register of shareholders kept by Euroclear Sweden AB ("Register of Shareholders") and complete the Proxy Form or the Electronic Proxy in accordance with the instructions set out below.

1. Registration Process for Voting Rights:

Direct-registered holders:

Holders of Euroclear Registered Cavotec Shares who hold their Euroclear Registered Cavotec Shares on an account directly with Euroclear Sweden, a CSD-account (Sw: Vp-konto), will be automatically included in the Register of Shareholders and do not have to perform any registration regarding voting rights.

Nominee-registered holders:

To be registered and entitled to vote at the OGM, shareholders who hold Euroclear Registered Cavotec Shares via a nominee ("Nominee-registered Holders") must act in accordance with the instructions set out below:

- Nominee-registered Holders must request the nominee to register their Euroclear Registered Cavotec Shares temporarily in their own name in the Register of Shareholders.
- The registration in the Register of Shareholders will start on March 24, 2016, 20 calendar days prior to the Record Date.
- The registration in the Register of Shareholders must be completed at End of Business Day at the Record Date at the latest.

Nominee-registered holders with Non-affiliated nominees:

To be registered and entitled to vote at the OGM, Nominee-registered Holders who hold their Euroclear Registered Cavotec Shares on custody accounts with Nominees that are not affiliated directly as nominees to Euroclear Sweden AB ("Nonaffiliated Nominee") must follow the instructions below:

- Nominee-registered Holders with Non-affiliated Nominees must request their custodian bank or their nominee to register their Euroclear Registered Cavotec Shares temporarily in their own name in the Register of Shareholders. To do so, you must instruct the institution where you have your account to forward the registration request to Euroclear Sweden AB through its own custodians and/or nominees.
- The registration in the Register of Shareholders will start on March 24, 2016, 20 calendar days prior to the Record Date.
- The registration in the Register of Shareholders must be completed at End of Business Day at the Record Date at the latest.

Please note that the registration process may take time in such circumstances. To ensure their registration, shareholders are therefore kindly invited to issue instructions to their Non-affiliated Nominees as soon as possible.

2. Registration/Proxy Voting:

Nominee-registered holders and direct-registered holders:

Holders of Euroclear Registered Cavotec Shares, registered on either a CSD-account (Sw Vp-konto) or a custody account with a nominee directly affiliated to Euroclear Sweden AB will receive a Proxy Form as well as the Individual Login by regular mail directly from Euroclear Sweden AB.

Recipients will be able to appoint a proxy or register to attend the OGM by using physical Proxy Forms. Recipients will also be able to grant a proxy and issue instructions to the independent proxy electronically by using the Electronic Proxy.

- In case Holders of Euroclear Registered Cavotec Shares intend to appoint a proxy or register to attend to the OGM, the Proxy Form must be filled out, signed, dated and returned to the addresses below well in advance of April 13, 2016. In order to vote by Electronic Proxy, the Electronic Proxy must be completed according to the instructions set out on <http://anmalan.vpc.se/Cavotec2016> by April 21 at the latest.

Nominee-registered Holders with Non-affiliated nominees:

In order to appoint a proxy or register to attend the OGM, Nominee-registered Holders with Non-affiliated nominees must:

- Download the Proxy Form the web site www.cavotec.com. The form will be available from February 25, 2016.
- Print and fill out the Proxy Form downloaded from www.cavotec.com and return it signed and to the address below well in advance of April 13, 2016. Alternatively, you may hand over your Proxy Form appointing the Independent Proxy as a proxy at the Information Meeting on April 22, 2016, in Stockholm, Sweden, until 30 minutes before the beginning of the OGM.

Additional Instructions for Non-affiliated nominees:

Non-affiliated nominees are urged to forward the above information to their custody-account holders holding Euroclear Registered Cavotec Shares.

3. Access to the OGM and Voting Rights:

To be granted access to the OGM and to enable voting right both the registration of voting rights as described above and the Proxy Form must be filled out and returned in accordance with the instructions set out above.

Even if you intend to participate in person, you must fill out the Proxy Form.

Frequently Asked Questions

Q1: I want to vote at the meeting of shareholders of Cavotec SA. Do I have to appoint a proxy or register to attend the Meeting?

A1: After having been registered (see below questions 3), you must either appoint Mr. Franco Brusa, Attorney-at-law (the independent proxy), or a third person as proxy or register to attend the OGM well in advance of April 13, 2016. Please note that you have to fill out the Proxy Form and send it to Mr. Franco Brusa, Attorney-at-law, c/o Euroclear Sweden AB, PO Box 191, SE-101 23 Stockholm, Sweden in case of proxies conferred to the independent proxy or to Cavotec SA, c/o Euroclear Sweden AB, PO Box 191, SE-101 23 Stockholm, Sweden for the other two cases. Please note that you can also appoint Mr. Franco Brusa, Attorney-at-law electronically by using the Electronic Proxy according to the instructions set out on <http://anmalan.vpc.se/Cavotec2016>. Alternatively, you may hand over your Proxy Form appointing the Independent Proxy as a proxy at the Information Meeting on April 22, 2016, in Stockholm, Sweden, until 30 minutes before the beginning of the OGM.

Q2: May I directly register for voting rights with Cavotec SA or send the Proxy Form to Cavotec SA or to Mr. Franco Brusa?

A2: Unfortunately, neither Cavotec SA nor Mr. Franco Brusa are able to register shareholders directly for the OGM or to process

Proxy Forms sent to them. Please contact Euroclear Sweden AB, telephone: +46 8 402 92 83 for more information. If you hold your shares through SIX SIS AG (see question 3 below) and need further assistance with questions related to registering your share in the share register of Cavotec SA, please contact your custodian bank or SIX SAG AG, telephone: +41 58 399 6120.

The following questions 3-5 are only relevant, if you have not already registered your shares for the OGM.

Q3: What do I have to do if I do not know whether I hold my Cavotec shares through SIX SIS AG or Euroclear Sweden AB or to which category of shareholders (i.e. Nominee-registered holders or direct-registered holders) I belong?

A3: Your custodian bank should be able to provide you with the required information. However, you may also contact Euroclear Sweden AB, telephone: +46 8 402 92 83 or SIX SAG AG, telephone: +41 58 399 6120 for further information. To register your shares, please follow the instructions set out above for the corresponding category of shareholders.

Q4: Who should I contact if I do not receive the necessary information/documents in connection with the OGM?

A4: Please contact Euroclear Sweden AB (telephone: +46 8 402 92 83).

Q5: When does the registration process for voting rights for shareholders who hold Cavotec Shares held through Euroclear Sweden AB via a nominee take place?

A5: The registration in the Register of Shareholders starts on March 24, 2016, 20 calendar days prior to the Record Date, and ends at 8 pm (CET) on April 13, 2016.

Personal Attendance / Proxy

You do not need to attend the OGM in person. You may appoint a proxy to represent you.

You can appoint the following persons to represent you:

- Mr Franco Brusa, Attorney-at-Law, Via G.B. Pioda 5, Lugano, Switzerland, has been appointed as independent shareholders' representative pursuant to Art. 9a of the Articles of Association. You may use the Proxy Form attached to this invitation or the Electronic Proxy as set out on <http://anmalan.vpc.se/Cavotec2016> to appoint and instruct the independent proxy; or
- any third person by contacting them directly.

NB: please sign, date and return the Registration/Appointment of Proxy Form in one of the enclosed envelopes by April 13, 2016 at latest, or complete the Electronic Proxy as set out on <http://anmalan.vpc.se/Cavotec2016> by April 21, 2016 at the latest. Alternatively, you may hand over your Proxy Form appointing the Independent Proxy as a proxy at the Information Meeting on April 22, 2015, in Stockholm, Sweden, until 30 minutes before the beginning of the OGM.

For questions regarding participation to the OGM, please contact:

Cavotec SA
c/o Euroclear Sweden AB
Box 191
SE-10123 Stockholm, Sweden
Telephone: +46 84029283

Lugano, 25 February 2016

For the Board of Directors of
Cavotec SA



Stefan Widegren
Chairman

